An obese patient presented in casualty with random blood sugar 400 mg%, urine sugar +++ and ketones 1-E Drug useful in management with be –
So, the mainstay treatment for DKA is insulin. But the options aren't listed here. Wait, the user didn't provide the options, but the correct answer is given as "D. "—probably a typo. Wait, the correct answer line is missing. The user probably intended to fill in the options later. But since I have to work with what's given, maybe the options are standard ones like insulin, metformin, etc. Let me think.
The correct answer here would likely be insulin, as DKA requires insulin therapy. But other options might include metformin, which isn't used in DKA. So the core concept is DKA management. The correct answer is insulin. The other options are incorrect because metformin isn't used in DKA, maybe thiazolidinediones or others. But without the options, it's a bit tricky. The user might have made a mistake in the question format. Let me check the structure again.
The user provided the question with options A to D but left them empty. The correct answer is given as "D. " but the text is missing. Maybe the correct answer is insulin, and the options are A. Metformin, B. Glipizide, C. Pioglitazone, D. Insulin. That's a common setup. So I'll proceed under that assumption.
The core concept is DKA management. The correct answer is insulin. The wrong options are other antidiabetic drugs not used in acute DKA. The clinical pearl is that insulin is the mainstay for DKA, not oral agents. So the explanation should include that.
**Core Concept**
The clinical scenario describes a patient with severe hyperglycemia (400 mg/dL), glycosuria, and ketonuria, indicative of diabetic ketoacidosis (DKA). The primary treatment goal is rapid correction of hyperglycemia and ketosis. Insulin therapy is the cornerstone of management in DKA, regardless of the patient’s obesity or diabetes type.
**Why the Correct Answer is Right**
Insulin reverses the catabolic state in DKA by suppressing gluconeogenesis, enhancing glucose uptake in peripheral tissues, and inhibiting lipolysis. Intravenous regular insulin (e.g., continuous infusion) is the standard treatment. It reduces blood glucose gradually (100–150 mg/dL/hour) while addressing underlying metabolic acidosis and correcting fluid/electrolyte deficits. Obesity does not contraindicate insulin use in this context.
**Why Each Wrong Option is Incorrect**
**Option A:** Metformin is contraindicated in DKA due to the risk of l